Breakthrough Targeted Therapy Shows Promise for KRAS‑Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key Role

FAIRFAX, Va., May 12, 2026 /PRNewswire/ -- Virginia Cancer Specialists announced today its participation as a leading clinical trial site in a landmark study evaluating daraxonrasib, a first‑in‑class targeted oral therapy for patients with previously treated, advanced KRAS‑mutated...